En
Design of novel molecules that are non-addictive and non-respiratory depressant.
Sustained-release microsphere injections which can provide analgesia and local anesthesia for more than 24 hours after single injection.
Sufentanil transdermal patch and other products have no first-pass effect and high bioavailability.
Drugs including Hydrocodone Sustained-release Tablets and Oxycodone Sustained-release Tablets, are designed to be difficult to crush, difficult to extract and difficult to be abused.
To make the blood concentration stable and the side effects reduced for hydromorphone sustained-release tablets.
Fententanil oral patches and other products are absorbed through mucous membranes and can take effect quickly.
Remazolam Besylate for Injection-Category 1 new drug
Remazolam Besylate for Injection (Brand name: RuiMa®) obtained the Drug Registration Certificate issued by National Medical Products Administration in July 2020.
Remazolam Besylate belongs to benzodiazepines and is a novel ultra-short-acting GABAA receptor agonist. It is metabolized by tissue esterase and the metabolites are inactive. Compared with similar products, it has the following clinical advantages: rapid onset of action, patient can wake quickly, lower respiratory/circulatory inhibition, there are specific antagonists, etc. In the future, it has wide applications in fields including painless diagnosis, treatment and sedation, general anesthesia, sedation in ICU, local anesthesia, and sedation.
Fospropofol Disodium for Injection-Category 1 new drug
Fospropofol Disodium for Injection (Brand name: LinBingFen®) obtained the Drug Registration Certificate issued by National Medical Products Administration in May 2021.
Fospropofol Disodium for Injection, is a new type of short-acting intravenously administered general anesthetic, and is also one of the most advanced intravenously administered general anesthetics studied at home and abroad. It is metabolized into the active substance propofol in the body to produce anesthetic effect and does not need the fat emulsion as vehicle of propofol preparations; during clinical application, it can reduce the pain of intravenous injection, and avoid the possible dyslipidemia caused by fat emulsion vehicle, bringing better surgical options for doctors and providing patients with a more comfortable experience of medical treatment.
Snowbellleaf Tickclover General Flavone Capsule-Category 1 new drug
Snowbellleaf Tickclover General Flavone Capsule (Brand name: Guang Shi Tong®) obtained the Drug Registration Certificate issued by National Medical Products Administration in September 2022.
Snowbellleaf Tickclover General Flavone Capsule, is a new Category 1.2 drug with independent intellectual property rights, which is obtained by extracting and purifying the effective parts of general flavone from the Snowbellleaf Tickclover using modern medical technology. Its major functions are to clear heat, expel damp, diuresis, and expel stone. It is used to treat ureteral calculi with accumulation of dampness and heat due to TCM differentiation. The product has the functions of diuresis, promoting stone discharge, anti-inflammatory effect, analgesia, etc. Compared with similar varieties, it can significantly improve the efficiency of stone removal in patients with ureteral calculi, especially for patients with large calculi who respond poorly to current medication treatment. It can reduce unnecessary surgical treatment, relieve patients' pain, reduce medical burden. Thus, it has a good value in clinical application.
Remazolam Besylate for Injection-Category 1 new drug
Remazolam Besylate for Injection (Brand name: RuiMa®) obtained the Drug Registration Certificate issued by National Medical Products Administration in July 2020.
Remazolam Besylate belongs to benzodiazepines and is a novel ultra-short-acting GABAA receptor agonist. It is metabolized by tissue esterase and the metabolites are inactive. Compared with similar products, it has the following clinical advantages: rapid onset of action, patient can wake quickly, lower respiratory/circulatory inhibition, there are specific antagonists, etc. In the future, it has wide applications in fields including painless diagnosis, treatment and sedation, general anesthesia, sedation in ICU, local anesthesia, and sedation.
Fospropofol Disodium for Injection-Category 1 new drug
Fospropofol Disodium for Injection (Brand name: LinBingFen®) obtained the Drug Registration Certificate issued by National Medical Products Administration in May 2021.
Fospropofol Disodium for Injection, is a new type of short-acting intravenously administered general anesthetic, and is also one of the most advanced intravenously administered general anesthetics studied at home and abroad. It is metabolized into the active substance propofol in the body to produce anesthetic effect and does not need the fat emulsion as vehicle of propofol preparations; during clinical application, it can reduce the pain of intravenous injection, and avoid the possible dyslipidemia caused by fat emulsion vehicle, bringing better surgical options for doctors and providing patients with a more comfortable experience of medical treatment.
Snowbellleaf Tickclover General Flavone Capsule-Category 1 new drug
Snowbellleaf Tickclover General Flavone Capsule (Brand name: Guang Shi Tong®) obtained the Drug Registration Certificate issued by National Medical Products Administration in September 2022.
Snowbellleaf Tickclover General Flavone Capsule, is a new Category 1.2 drug with independent intellectual property rights, which is obtained by extracting and purifying the effective parts of general flavone from the Snowbellleaf Tickclover using modern medical technology. Its major functions are to clear heat, expel damp, diuresis, and expel stone. It is used to treat ureteral calculi with accumulation of dampness and heat due to TCM differentiation. The product has the functions of diuresis, promoting stone discharge, anti-inflammatory effect, analgesia, etc. Compared with similar varieties, it can significantly improve the efficiency of stone removal in patients with ureteral calculi, especially for patients with large calculi who respond poorly to current medication treatment. It can reduce unnecessary surgical treatment, relieve patients' pain, reduce medical burden. Thus, it has a good value in clinical application.